Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Studying Gene Expression and Location in Samples From Patients With Brain Tumors

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01585389
First received: April 24, 2012
Last updated: May 17, 2016
Last verified: May 2016
  Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to brain tumors.

PURPOSE: This research studies gene expression and location in samples from patients with brain tumors.


Condition Intervention
Brain and Central Nervous System Tumors
Genetic: gene expression analysis
Genetic: genetic linkage analysis
Genetic: microarray analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Expression and Subcellular Localization of NEIL3 in Tumors

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Correlation of NEIL3 expression and/or nuclear localization with tumor type or grade with respect to degree of differentiation [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: April 2012
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To determine the expression and subcellular localization of nei endonuclease VIII-like 3 (NEIL3) in brain tumors.

OUTLINE: Tissue microarray samples are analyzed for NEIL3 expression and subcellular localization by immunohistochemical methods.

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with brain tumors
Criteria

DISEASE CHARACTERISTICS:

  • Tissue microarrays (TMA) samples from the Biopathology Core
  • Samples from patients diagnosed with brain tumors

    • Progenitor, or blast, cell origin

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01585389

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Principal Investigator: Heithem M. El-Hodiri, PhD Nationwide Children's Hospital
  More Information

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT01585389     History of Changes
Other Study ID Numbers: ABTR12B3  COG-ABTR12B3  ABTR12B3  CDR0000732178  NCI-2012-00731 
Study First Received: April 24, 2012
Last Updated: May 17, 2016
Health Authority: United States: Federal Government

Keywords provided by Children's Oncology Group:
adult brain tumor
childhood brain tumor

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Nervous System Diseases

ClinicalTrials.gov processed this record on September 23, 2016